Medifocus Inc (MDFZF) 0.0367 $MDFZF
GroGenesis Announces New Chairman of the Board of Directors
Marketwired - Thu Oct 08, 12:42PM CDT
GroGenesis, Inc., (OTCQB: GROG), the rights holder, developer and manufacturer of innovative agricultural enhancement products marketed under the trade names "AgraBurst" and "AgraBlast," announced today the appointment of Grant B. Walsh as a Director and Chairman of the Board of Directors of GroGenesis, effective immediately.
Medifocus, Inc. Presentation Now Available for On-Demand Viewing
CNW Group - Tue Oct 06, 7:00AM CDT
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MFS.VN: 0.050 (unch)
Medifocus, Inc. Announces Approach of Major Milestone of 100,000 Prolieve(R) Treatments
Marketwire Canada - Wed Sep 30, 10:04AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a biotechnology company with a portfolio of medical technologies that utilizes heat-activation to treat conditions ranging from urological problems to breast cancer treatment and extends to gene therapy, announced today that, based on the total number of single use Prolieve(R) Kits sold to date, a milestone of 100,000 men with Benign Prostatic Hyperplasia (BPH) treated with the Prolieve(R) system, is rapidly approaching. Prolieve(R) offers a unique "Thermodilatation" treatment for BPH. Thermodilatation is a combinational therapy using Transurethral Microwave Therapy (TUMT) together with cooled and pressurized balloon dilatation therapy simultaneously.
MFS.VN: 0.050 (unch)
Medifocus, Inc. to Present Live via Webcast at VirtualInvestorConferences.com on October 1, 2015 at 10:45am ET
PR Newswire - Tue Sep 29, 7:55AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
MFS.VN: 0.050 (unch)
Medifocus Inc. Announces Units Offering
CNW Group - Mon Sep 28, 4:07PM CDT
Medifocus Inc. (TSX VENTURE:MFS) (OTCQX:MDFZF) ("Medifocus" or the "Company"
announces, subject to regulatory approval, a non-brokered private placement of up to 500 units (the "Units" at a price of U.S. $10,000 per Unit for anticipated gross proceeds of up to U.S. $5,000,000 (the Offering). Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants. Each Series F Common Share purchase warrant entitles the holder to purchase one additional Common Share at a price of U.S. $0.10 for a period of 24 months following the completion of the Offering. If, at any time prior to the warrants' expiration date, the daily volume weighted average trading price of the Common Shares exceeds U.S. $0.20 on the OTCQX in the United States, or its equivalent in Canadian dollars on the TSX Venture Exchange in Canada for at least 10 consecutive trading days, Medifocus may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given. Medifocus may pay finder's fees equal to 7% of the gross proceeds.
MFS.VN: 0.050 (unch)
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
Medifocus, Inc. Appoints Christopher Kaplan to Its Strategic Advisory Board
Marketwire Canada - Tue Jun 16, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has appointed Christopher Kaplan as a member of the its recently formed Strategic Advisory Board (SAB).
MFS.VN: 0.050 (unch)
Medifocus, Inc. Appoints Joseph M. Chalil to Its Strategic Advisory Board
Marketwired - Thu Jun 04, 8:01AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has established a Strategic Advisory Board (SAB) and has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, as one of the Company's Strategic Business Advisors.
MFS.VN: 0.050 (unch)
Medifocus, Inc. Announces Option Agreement With Major Academic Medical Center to License Technology to Develop Heat Activated and Tumor Targeted Immunotherapy
Marketwired - Wed May 27, 7:00AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has entered into an option agreement with Duke University regarding heat-activated and tumor targeted Immunotherapy. The two parties are actively negotiating an exclusive license to the Patent Rights of a Duke invention for the development of heat-activated and tumor targeted Immunotherapy for treatment of cancer and other diseases. This option to license and develop Duke's technology runs through December 30, 2015.
MFS.VN: 0.050 (unch)
Medifocus, Inc. Closes Equity Offering
Marketwire Canada - Tue May 12, 10:48AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) today announced that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 13, 2015.
MFS.VN: 0.050 (unch)
Medifocus Announces Retraction of Prior Press Release
Marketwire Canada - Mon May 11, 3:26PM CDT
Medifocus, Inc. (Medifocus) (OTCQX: MDFZF) (TSX VENTURE: MFS) issued a press release earlier today regarding an equity offering that inadvertently announced the completion of the offering. Medifocus hereby retracts this press release.
MFS.VN: 0.050 (unch)
Medifocus, Inc. Announces Equity Offering
Marketwire Canada - Mon May 11, 2:08PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announces that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of up to $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 11, 2015.
MFS.VN: 0.050 (unch)
GroGenesis Announces New Chairman of the Board of Directors
Marketwired - Thu Oct 08, 12:42PM CDT
GroGenesis, Inc., (OTCQB: GROG), the rights holder, developer and manufacturer of innovative agricultural enhancement products marketed under the trade names "AgraBurst" and "AgraBlast," announced today the appointment of Grant B. Walsh as a Director and Chairman of the Board of Directors of GroGenesis, effective immediately.
Medifocus, Inc. Presentation Now Available for On-Demand Viewing
CNW Group - Tue Oct 06, 7:00AM CDT
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MFS.VN: 0.050 (unch)
Medifocus, Inc. Announces Approach of Major Milestone of 100,000 Prolieve(R) Treatments
Marketwire Canada - Wed Sep 30, 10:04AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a biotechnology company with a portfolio of medical technologies that utilizes heat-activation to treat conditions ranging from urological problems to breast cancer treatment and extends to gene therapy, announced today that, based on the total number of single use Prolieve(R) Kits sold to date, a milestone of 100,000 men with Benign Prostatic Hyperplasia (BPH) treated with the Prolieve(R) system, is rapidly approaching. Prolieve(R) offers a unique "Thermodilatation" treatment for BPH. Thermodilatation is a combinational therapy using Transurethral Microwave Therapy (TUMT) together with cooled and pressurized balloon dilatation therapy simultaneously.
MFS.VN: 0.050 (unch)
Medifocus, Inc. to Present Live via Webcast at VirtualInvestorConferences.com on October 1, 2015 at 10:45am ET
PR Newswire - Tue Sep 29, 7:55AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
MFS.VN: 0.050 (unch)
Medifocus Inc. Announces Units Offering
CNW Group - Mon Sep 28, 4:07PM CDT
Medifocus Inc. (TSX VENTURE:MFS) (OTCQX:MDFZF) ("Medifocus" or the "Company"
announces, subject to regulatory approval, a non-brokered private placement of up to 500 units (the "Units" at a price of U.S. $10,000 per Unit for anticipated gross proceeds of up to U.S. $5,000,000 (the Offering). Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants. Each Series F Common Share purchase warrant entitles the holder to purchase one additional Common Share at a price of U.S. $0.10 for a period of 24 months following the completion of the Offering. If, at any time prior to the warrants' expiration date, the daily volume weighted average trading price of the Common Shares exceeds U.S. $0.20 on the OTCQX in the United States, or its equivalent in Canadian dollars on the TSX Venture Exchange in Canada for at least 10 consecutive trading days, Medifocus may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given. Medifocus may pay finder's fees equal to 7% of the gross proceeds. MFS.VN: 0.050 (unch)
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
Medifocus, Inc. Appoints Christopher Kaplan to Its Strategic Advisory Board
Marketwire Canada - Tue Jun 16, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has appointed Christopher Kaplan as a member of the its recently formed Strategic Advisory Board (SAB).
MFS.VN: 0.050 (unch)
Medifocus, Inc. Appoints Joseph M. Chalil to Its Strategic Advisory Board
Marketwired - Thu Jun 04, 8:01AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has established a Strategic Advisory Board (SAB) and has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, as one of the Company's Strategic Business Advisors.
MFS.VN: 0.050 (unch)
Medifocus, Inc. Announces Option Agreement With Major Academic Medical Center to License Technology to Develop Heat Activated and Tumor Targeted Immunotherapy
Marketwired - Wed May 27, 7:00AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has entered into an option agreement with Duke University regarding heat-activated and tumor targeted Immunotherapy. The two parties are actively negotiating an exclusive license to the Patent Rights of a Duke invention for the development of heat-activated and tumor targeted Immunotherapy for treatment of cancer and other diseases. This option to license and develop Duke's technology runs through December 30, 2015.
MFS.VN: 0.050 (unch)
Medifocus, Inc. Closes Equity Offering
Marketwire Canada - Tue May 12, 10:48AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) today announced that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 13, 2015.
MFS.VN: 0.050 (unch)
Medifocus Announces Retraction of Prior Press Release
Marketwire Canada - Mon May 11, 3:26PM CDT
Medifocus, Inc. (Medifocus) (OTCQX: MDFZF) (TSX VENTURE: MFS) issued a press release earlier today regarding an equity offering that inadvertently announced the completion of the offering. Medifocus hereby retracts this press release.
MFS.VN: 0.050 (unch)
Medifocus, Inc. Announces Equity Offering
Marketwire Canada - Mon May 11, 2:08PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announces that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of up to $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 11, 2015.
MFS.VN: 0.050 (unch)
